Physician profile
Klaus P Rentrop
NPI 1194723601
$5,634,198.55
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4.2M · 2020: $1.4M · 2021: $192.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $5,633,968.61 | 2019-2020 | |
| Abbott Laboratories | $68.48 | 2021 | |
| Astellas Pharma US INC | $37.52 | 2019 | |
| Novo Nordisk INC | $37.13 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.25 | 2021 | |
| Merck Sharp & Dohme LLC | $18.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.22 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $16.90 | 2021 | |
| Medtronic, INC. | $12.01 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Klaus Rentrop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.